Efficacy and prognostic factors of autologous hematopoietic stem cell transplantation for multiple myeloma: clinical analysis of 53 cases

Renke HE; Xin WANG; Xiaohua LUO; Xiaoqiong TANG; Qing XIAO; Hongbin ZHANG; Jianbin CHEN; Lin LIU; Li WANG

doi:10.16016/j.1000-5404.202010015

您当前的位置：

首页 >

文章列表页 >

Efficacy and prognostic factors of autologous hematopoietic stem cell transplantation for multiple myeloma: clinical analysis of 53 cases

更新时间：2026-01-09

- Efficacy and prognostic factors of autologous hematopoietic stem cell transplantation for multiple myeloma: clinical analysis of 53 cases
- Journal of Third Military Medical University Vol. 43, Issue 6, Pages: 553-559(2021)
- 作者机构：
- 作者简介：
- 基金信息：
  
  the Key Project of Joint Medical Research of Chongqing Science and Technology Commission and Chongqing Municipal Health Commission(2018ZDXM001)
- DOI：10.16016/j.1000-5404.202010015
  CLC：
- Received：09 October 2020，
  
  Published：30 March 2021
- 稿件说明：
移动端阅览
Renke HE, Xin WANG, Xiaohua LUO, et al. Efficacy and prognostic factors of autologous hematopoietic stem cell transplantation for multiple myeloma: clinical analysis of 53 cases[J]. Journal of Third Military Medical University, 2021, 43(6): 553-559.
DOI：

Renke HE, Xin WANG, Xiaohua LUO, et al. Efficacy and prognostic factors of autologous hematopoietic stem cell transplantation for multiple myeloma: clinical analysis of 53 cases[J]. Journal of Third Military Medical University, 2021, 43(6): 553-559. DOI： 10.16016/j.1000-5404.202010015.

摘要

Abstract

Objective

To evaluate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) on multiple myeloma (MM) and to investigate the factors affecting the prognosis.

Methods

The clinical data of 53 MM patients treated with auto-HSCT in our hospital from January 2010 to December 2019 were collected and retrospectively analyzed. The therapeutic effect was observed and the prognostic factors were analyzed.

Results

Hematopoietic reconstruction was achieved in all 53 patients

and no transplant-related death occurred. As complete remission (CR) and very good partial remission (VGPR) were defined as effective response

the rate was 84.9% after transplantation

significantly higher than that before treatment (52.8%)(

0.001). The effective remission rates were 52.2% and 84.8%

respectively

before and after treatment in the 46 patients with single transplantation (

=0.001). However

the rates were 57.1% and 85.7% respectively for the 7 patients with consecutive double transplantation (

=0.559). There were no significant differences in progression-free survival (PFS) and overall survival (OS) between the single and continuous double transplantation patients (

0.05). Influential factors for poor prognosis were identified as: age≥50 years

stage Ⅲ by revised international staging system (R-ISS)

time from diagnosis to transplantation ≥180 d

high-risk stratification

partial remission (PR) or worse before and after transplantation

as well as positive results of minimal residual disease (MRD) test before and after treatment.

Conclusion

Auto-HSCT is safe and effective in MM patients

and can significantly improve the remission rate and prognosis. Single transplantation is better than continuous double treatment in the effectiveness. R-ISS stage

risk stratification

disease status before and after transplantation

and result of MRD test are closely associated with the prognosis of the patients.

关键词

Keywords

references

WANG S F XU L FENG J N Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis Front Oncol 2020 9 1513 10.3389/fonc.2019.01513 WANG S F, XU L, FENG J N, et al . Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis[J ] . Front Oncol, 2020, 9: 1513. DOI: 10.3389/fonc.2019.01513.

RAJKUMAR S V DIMOPOULOS M A PALUMBO A International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet Oncol 2014 15 12 e538 e548 10.1016/S1470-2045(14)70442-5 RAJKUMAR S V, DIMOPOULOS M A, PALUMBO A, et al . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J ] . Lancet Oncol, 2014, 15(12): e538-e548. DOI: 10.1016/S1470-2045(14)70442-5.

KUMAR S PAIVA B ANDERSON K C International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Lancet Oncol 2016 17 8 e328 e346 10.1016/S1470-2045(16)30206-6 KUMAR S, PAIVA B, ANDERSON K C, et al . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J ] . Lancet Oncol, 2016, 17(8): e328-e346. DOI: 10.1016/S1470-2045(16)30206-6.

PALUMBO A Hevre A STEFANIA O Revised international staging system for multiple myeloma: a report from international myeloma working group J Clin Oncol 2015 33 26 2863 2869 10.1200/JCO.2015.61.2267 PALUMBO A, Hevre A, STEFANIA O, et al . Revised international staging system for multiple myeloma: a report from international myeloma working group[J ] . J Clin Oncol, 2015, 33(26): 2863-2869. DOI: 10.1200/JCO.2015.61.2267.

贾雁春杜鹃多发性骨髓瘤的预后评估体系临床检验杂志 2019 37 11 820 824 https://www.cnki.com.cn/Article/CJFDTOTAL-LCJY201911006.htm 贾雁春, 杜鹃. 多发性骨髓瘤的预后评估体系[J]. 临床检验杂志, 2019, 37(11): 820-824.

JIA Y C DU J Prognostic evaluation system for multiple myeloma J Clin Lab 2019 37 11 820 824 https://www.cnki.com.cn/Article/CJFDTOTAL-LCJY201911006.htm JIA Y C, DU J, Prognostic evaluation system for multiple myeloma[J]. J Clin Lab, 2019, 37 (11): 820-824.

CHAKRABORTY R MUCHTAR E KUMAR S The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents Bone Marrow Transplant 2017 52 1 34 40 10.1038/bmt.2016.214 CHAKRABORTY R, MUCHTAR E, KUMAR S, et al . The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents[J ] . Bone Marrow Transplant, 2017, 52(1): 34-40. DOI: 10.1038/bmt.2016.214.

张雯洁 . 自体造血干细胞移植与新药治疗多发性骨髓瘤疗效与安全性比较的Meta分析 [D ] . 兰州 : 甘肃中医药大学 , 2015 . 张雯洁. 自体造血干细胞移植与新药治疗多发性骨髓瘤疗效与安全性比较的Meta分析[D]. 兰州: 甘肃中医药大学, 2015.

ZHANG W J , Meta-analysis on the comparison of efficacy and safety between autologous hematopoietic stem cell transplantation and new drugs for multiple myeloma [D ] . Lanzhou : Gansu University of Chinese Medicine , 2015 . ZHANG W J, Meta-analysis on the comparison of efficacy and safety between autologous hematopoietic stem cell transplantation and new drugs for multiple myeloma[D]. Lanzhou: Gansu University of Chinese Medicine, 2015.

隋伟薇邹德慧安刚多发性骨髓瘤患者自体造血干细胞移植后长期随访的单中心结果中华血液学杂志 2017 38 6 499 504 隋伟薇, 邹德慧, 安刚, 等. 多发性骨髓瘤患者自体造血干细胞移植后长期随访的单中心结果[J]. 中华血液学杂志, 2017, 38(6): 499-504.

SUI W W ZOU D H AN G Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results Chin J Hematol 2017 38 6 499 504 SUI W W, ZOU D H, AN G, et al . Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results[J ] . Chin J Hematol, 2017, 38(6): 499-504.

王超雨夏冰宁乔杨 56例多发性骨髓瘤行患者自体造血干细胞移植治疗的临床疗效分析中国实验血液学杂志 2018 26 5 1396 1402 https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201805026.htm 王超雨, 夏冰, 宁乔杨, 等. 56例多发性骨髓瘤行患者自体造血干细胞移植治疗的临床疗效分析[J]. 中国实验血液学杂志, 2018, 26(5): 1396-1402.

WANG C Y XIA B NING Q Y Clinical effect of autologous hematopoietic stem cell transplantation in 56 patients with multiple myeloma Chin J Exp Hematol 2018 26 5 1396 1402 https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201805026.htm WANG C Y, XIA B, NING Q Y, et al . Clinical effect of autologous hematopoietic stem cell transplantation in 56 patients with multiple myeloma[J ] . Chin J Exp Hematol, 2018, 26(5): 1396-1402.

LEHNERS N BECKER N BENNER A Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response Cancer Med 2018 7 2 307 316 10.1002/cam4.1283 LEHNERS N, BECKER N, BENNER A, et al . Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response[J ] . Cancer Med, 2018, 7(2): 307-316. DOI: 10.1002/cam4.1283.

IACOBELLI S DE WREEDE L C SCHÖNLAND S Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial Bone Marrow Transplant 2015 50 4 505 510 10.1038/bmt.2014.310 IACOBELLI S, DE WREEDE L C, SCHÖNLAND S, et al . Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial[J ] . Bone Marrow Transplant, 2015, 50(4): 505-510. DOI: 10.1038/bmt.2014.310.

PAIVA B VIDRIALES M B CERVER 0JJ Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation Blood 2008 112 10 4017 4023 10.1182/blood-2008-05-159624 PAIVA B, VIDRIALES M B, CERVER 0JJ, et al . Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation[J ] . Blood, 2008, 112(10): 4017-4023. DOI: 10.1182/blood-2008-05-159624.

LAHUERTA J J PAIVA B VIDRIALES M B Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials J Clin Oncol 2017 35 25 2900 2910 10.1200/jco.2016.69.2517 LAHUERTA J J, PAIVA B, VIDRIALES M B, et al . Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials[J ] . J Clin Oncol, 2017, 35(25): 2900-2910. DOI: 10.1200/jco.2016.69.2517.

GAO M J YANG G HAN Y Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials Int J Clin Exp Med 2015 8 8 12202 12210 http://europepmc.org/articles/PMC4612815 GAO M J, YANG G, HAN Y, et al . Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials[J ] . Int J Clin Exp Med, 2015, 8(8): 12202-12210.

ROSIÑOL L ORIOL A TERUEL A I Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial Leukemia 2017 31 9 1922 1927 10.1038/leu.2017.35 ROSIÑOL L, ORIOL A, TERUEL A I, et al . Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial[J ] . Leukemia, 2017, 31(9): 1922-1927. DOI: 10.1038/leu.2017.35.

TAMURA H Single vs double stem cell transplantation for the treatment of multiple myeloma Nihon Rinsho Jpn J Clin Med 2015 73 1 85 89 http://europepmc.org/abstract/med/25626310 TAMURA H. Single vs double stem cell transplantation for the treatment of multiple myeloma[J]. Nihon Rinsho Jpn J Clin Med, 2015, 73(1): 85-89.

CAVO M TOSI P ZAMAGNI E Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study J Clin Oncol 2007 25 17 2434 2441 10.1200/jco.2006.10.2509 CAVO M, TOSI P, ZAMAGNI E, et al . Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study[J ] . J Clin Oncol, 2007, 25(17): 2434-2441. DOI: 10.1200/jco.2006.10.2509.

EOM K S MIN C K LEE S Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma Jpn J Clin Oncol 2006 36 7 432 438 10.1093/jjco/hyl041 EOM K S, MIN C K, LEE S, et al . Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma[J ] . Jpn J Clin Oncol, 2006, 36(7): 432-438. DOI: 10.1093/jjco/hyl041.

KUMAR A KHARFAN-DABAJA M DJULBEGOVIC B Response: re: tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis J Natl Cancer Inst 2009 101 20 1431 1433 10.1093/jnci/djp321 KUMAR A, KHARFAN-DABAJA M, DJULBEGOVIC B. Response: re: tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis[J]. J Natl Cancer Inst, 2009, 101(20): 1431-1433. DOI: 10.1093/jnci/djp321.

金媛媛庄俊玲新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位协和医学杂志 2018 9 3 219 223 https://www.cnki.com.cn/Article/CJFDTOTAL-XHYX201803006.htm 金媛媛, 庄俊玲. 新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位[J]. 协和医学杂志, 2018, 9(3): 219-223.

JIN Y Y ZHUANG J L Autologous stem cell transplantation for multiple myeloma in the era of novel medicines Med J PUMCH 2018 9 3 219 223 https://www.cnki.com.cn/Article/CJFDTOTAL-XHYX201803006.htm JIN Y Y, ZHUANG J L. Autologous stem cell transplantation for multiple myeloma in the era of novel medicines[J]. Med J PUMCH, 2018, 9(3): 219-223.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Construction and validation of a prognostic model based on cuproptosis-related genes in patients with multiple myeloma

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma

Expression of HMGCS2 and its correlation with clinopathological characteristics in bladder cancer

Influence of targeted inhibition of DNAJC1 gene on apoptosis and proliferation in multiple myeloma cells

Related Author

WU Zhenzhen

CAO Tingyong

FENG Youfan

ZHAO Li

KANG Zhongmin

LI Licheng

HUANG Yuying

WANG Jishi

Related Institution

The First Clinical Medical College， Lanzhou University

Department of Hematology， the Second Hospital & Clinical Medical School， Lanzhou University

Department of Hematology， Gansu Provincial Hospital

Gansu Provincial Clinical Medical Research Center for Molecular Diagnosis and Treatment of Hematological Diseases， the First Hospital， Lanzhou University

The Laboratory Center， the First Hospital， Lanzhou University

⁰